Interactive effect of histamine and prostaglandin D2 on nasal allergic symptoms in rats.
This study was undertaken to investigate the interactive effect of histamine and prostaglandin D(2) in nasal allergic symptoms in rats. The intranasal application of histamine at doses lower than 10 mumol/site caused no sneezing or nasal rubbing. In addition, prostaglandin D(2) also showed no significant increase in these responses, even at a dose of 10 nmol/site. On the other hand, the simultaneous instillation of histamine and prostaglandin D(2) resulted in a 1000 times more potent effect in inducing nasal symptoms than the administration of histamine alone. Thus, prostaglandin D(2) enhanced the actions of histamine in inducing sneezing and nasal rubbing in a dose-dependent manner, and significant effects were observed at doses higher than 1 nmol/site. The responses induced by the simultaneous application of histamine and prostaglandin D(2) were inhibited by chlorpheniramine, cyproheptadine, BW A868C and ramatroban. Chlorpheniramine and cyproheptadine showed the dose-related inhibition of nasal symptoms induced by the combined administration of histamine (10 nmol) and prostaglandin D(2) (10 nmol), but the effect of cyproheptadine was relatively weak compared with chlorpheniramine. Moreover, BW A868C and ramatroban also showed the inhibition of nasal symptoms induced by the simultaneous administration of histamine and prostaglandin D(2) in a dose-dependent manner. BW A868C was more potent in inhibiting the nasal symptoms than ramatroban. These results clearly indicate that prostaglandin D(2) showed a synergistic effect on sneezing and nasal rubbing induced by histamine in rats, and its effect occurred through both prostaglandin D(2) and CRTH2 (chemoattractant receptor-homologous molecule expressed on TH2 cells) receptors.
Rahman
Ashequr
A
Department of Medicinal Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Tsushima-naka 1-1-1, Okayama 700-8530, Japan.
Inoue
Toshio
T
Ago
Jun
J
Ishikawa
Takashi
T
Kamei
Chiaki
C
D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D002227:Carbazoles / Q000008:administration & dosage / Q000494:pharmacology; D002744:Chlorpheniramine / Q000008:administration & dosage / Q000494:pharmacology; D003533:Cyproheptadine / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006632:Histamine / Q000008:administration & dosage* / Q000276:immunology; D018494:Histamine Agents / Q000008:administration & dosage / Q000276:immunology; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D006827:Hydantoins / Q000008:administration & dosage / Q000494:pharmacology; D007275:Injections, Intravenous; D009297:Nasal Mucosa / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D015230:Prostaglandin D2 / Q000008:administration & dosage* / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors; D012220:Rhinitis / Q000139:chemically induced / Q000517:prevention & control; D012912:Sneezing / Q000187:drug effects* / Q000276:immunology; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology
D002227:Carbazoles; D018494:Histamine Agents; D006634:Histamine H1 Antagonists; D006827:Hydantoins; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D013449:Sulfonamides; C058848:BW A868C; D003533:Cyproheptadine; D002744:Chlorpheniramine; D006632:Histamine; C063119:ramatroban; D015230:Prostaglandin D2; C036293:prostaglandin D2 receptor